Imagen de Portada

Letter on ‘Clinical Trial: Effect of a 28‐Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis ( EndoFOD )—A Randomised, Controlled Crossover Feeding Study’

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Wancheng Zhao, Lei Yu, Jiao Wang
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter: Rifaximin Versus Low FODMAP Diet in IBS : What the Primary Endpoint Does Not Tell Us
por: Luisa Bertin, et al.
Publicado: (2026)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial
por: Yu Yang, et al.
Publicado: (2024)

Letter: Incidence and Predictors of Major Gastrointestinal Bleeding in Patients on Aspirin, Low‐Dose Rivaroxaban or the Combination: Secondary Analysis of the COMPASS Randomised Controlled Trial. Authors' Reply
por: Nauzer Forbes, et al.
Publicado: (2024)

Editorial: Personalising the Low FODMAP Diet to Achieve Therapeutic Benefit Whilst Reducing Burden and Maintaining Dietary Diversity in Irritable Bowel Syndrome. Authors' Reply
por: E. Coss‐Adame, et al.
Publicado: (2026)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
por: Veeral Ajmera, et al.
Publicado: (2026)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
por: Sofia Tsitsou, et al.
Publicado: (2025)

Letter: Interpreting Apparent P‐ CAB Superiority for Antithrombotic‐Associated Upper Gastrointestinal Bleeding
por: Xiaoqing Yang, et al.
Publicado: (2026)

Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis—A Randomised Controlled Trial
por: Ankit Kumar, et al.
Publicado: (2026)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
por: Hassan Javed, et al.
Publicado: (2025)

Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials
por: Matheus Souza, et al.
Publicado: (2025)

Letter: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral Anticoagulants
por: Jiaqi Shen, et al.
Publicado: (2026)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
por: Mohamed El‐Kassas, et al.
Publicado: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
por: Zhidong Zhou, et al.
Publicado: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
por: Shoko Miyahara, et al.
Publicado: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
por: Alice S. Day, et al.
Publicado: (2025)

The Association of Faecal Calprotectin Measurements With Endo‐Histological Remission in Ulcerative Colitis: A Pooled Analysis
por: Laurie‐Rose Dubé, et al.
Publicado: (2026)

Research Communication: Teriflunomide Does Not Affect Gluten‐Specific T‐Cell Activity in Coeliac Disease—A Randomised, Placebo‐Controlled Trial
por: Louise F. Risnes, et al.
Publicado: (2025)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
por: Kee Huat Chuah, et al.
Publicado: (2025)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
por: Iris Barth, et al.
Publicado: (2024)

Letter on ‘Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis’
por: Yi Pei, et al.
Publicado: (2025)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
por: Liang Jiao, et al.
Publicado: (2026)

Research Communication: Effects of Screening Colonoscopy on Colorectal Cancer Mortality: Lessons From Comparative Analyses of Randomised Trials
por: Hermann Brenner, et al.
Publicado: (2025)

Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT ‐ UC Consortium
por: Brian C. Weiner
Publicado: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
por: YaoYao Dai, et al.
Publicado: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
por: Maria Buti
Publicado: (2025)

Letter: Myokines Are Also Associated With Disease Course in Primary Biliary Cholangitis
por: Leyu Zhou, et al.
Publicado: (2024)

Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation
por: Yuan‐Yuan Zhang, et al.
Publicado: (2025)

Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments
por: Chen‐Pi Li, et al.
Publicado: (2024)

Letter: Association between terlipressin and multi‐drug‐resistant organism rectal colonisation
por: Katrina Tan, et al.
Publicado: (2024)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
por: Bi‐Yu Gao, et al.
Publicado: (2025)

Letter: Gas‐Sensing Capsules Advance Colonic Physiology Research Toward Clinical Translation
por: Anastasios Koulaouzidis, et al.
Publicado: (2025)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)
por: Marco Sanduzzi‐Zamparelli, et al.
Publicado: (2026)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
por: Benjamin Douglas Liu, et al.
Publicado: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
por: Wen‐Juei Jeng, et al.
Publicado: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
por: Cong Dai, et al.
Publicado: (2024)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
por: Yu‐Sheng Lin, et al.
Publicado: (2026)

Letter: Meta‐Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis
por: Haleema Rahman
Publicado: (2025)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
por: Marcus M. Mücke, et al.
Publicado: (2024)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
por: Stergios A. Polyzos, et al.
Publicado: (2024)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
por: Lukas Burghart, et al.
Publicado: (2026)